All Trials

Phase II Non-Randomized, Unblinded, Single-Center Trial of Telmisartan in Combination With Cytotoxic Regimens in Platinum-Resistant Ovarian Cancer Versus Historical Best Supportive Care

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with platinum-resistant or platinum-refractory high-grade serous ovarian carcinoma (ECOG 0–2) receive oral telmisartan, an angiotensin II type 1 receptor (AT1R) blocker, added to investigator-selected standard cytotoxic chemotherapy (preferred pegylated liposomal doxorubicin; or paclitaxel/nab-paclitaxel/docetaxel), with outcomes compared against historical best supportive care. The study assesses whether this combination improves progression-free survival and evaluates ctDNA dynamics and tolerability.

ClinicalTrials.gov ID: NCT06815497

Randomized Phase III Study of Second-Line Chemotherapy With or Without Panitumumab for KRAS Wild Type, Locally Advanced or Metastatic Pancreatic Adenocarcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma that is tissue-confirmed KRAS wild type and BRAF V600E wild type, ECOG 0–2, who have progressed on/intolerant of exactly one prior systemic cytotoxic regimen for advanced disease. Patients are randomized to investigator-chosen second-line chemotherapy (nal-IRI/5-FU/LV, irinotecan/5-FU/LV, or nab-paclitaxel/gemcitabine) with or without panitumumab, an anti-EGFR monoclonal antibody that blocks EGFR signaling.

ClinicalTrials.gov ID: NCT06998940

A Phase II, Randomized, Multicenter, Open-Label Study Evaluating the Efficacy and Safety of the Combination of Inavolisib Plus Enzalutamide Versus Physician's Choice of ARPI or Docetaxel in Patients With Metastatic Castration-Resistant Prostate Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with progressive metastatic castration-resistant prostate adenocarcinoma (no neuroendocrine/small-cell features), ECOG 0–1, after progression on exactly one prior second-generation AR pathway inhibitor and with FoundationOne CDx–selected PI3K-pathway biomarker/tissue available (excluding liver metastases and abnormal baseline glycemia/diabetes). Randomized to inavolisib (oral selective PI3Kα inhibitor) plus enzalutamide versus physician’s choice of alternate ARPI (abiraterone or enzalutamide) or docetaxel.

ClinicalTrials.gov ID: NCT07287150

Phase II Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with extensive-stage (or locally advanced non-curable) small cell lung cancer who have completed 4–6 cycles of first-line platinum/etoposide plus atezolizumab or durvalumab and have CR/PR/SD without progression (ECOG 0–2; stable asymptomatic brain metastases allowed) receive maintenance sacituzumab govitecan, a TROP-2–directed antibody–drug conjugate delivering SN-38, combined with ongoing PD-L1 inhibitor maintenance (atezolizumab or durvalumab) until progression/toxicity (up to 2 years).

ClinicalTrials.gov ID: NCT07339059

A Randomized Phase II Study of Amivantamab (JNJ-61186372) and Hyaluronidase (rHuPH20) Versus Cetuximab in Immunocompromised Participants With Recurrent Inoperable or Metastatic Cutaneous Squamous Cell Carcinoma

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Adults with locally recurrent inoperable/locoregionally incurable or metastatic cutaneous squamous cell carcinoma who are actively immunocompromised (e.g., solid organ transplant recipients, hematologic malignancy, or autoimmune disease on immunosuppressants; ECOG 0–2; no recent EGFR inhibitor) are treated with subcutaneous amivantamab plus rHuPH20, a bispecific anti-EGFR/MET antibody (hyaluronidase to enable SC delivery), with an initial safety cohort and a randomized cohort comparing progression-free survival versus IV cetuximab (anti-EGFR).

ClinicalTrials.gov ID: NCT07042295

A Randomized Phase III Trial of Carboplatin, Paclitaxel, Pembrolizumab Versus Carboplatin, Paclitaxel, Bevacizumab Versus Carboplatin, Paclitaxel, Pembrolizumab, Bevacizumab in the Treatment of pMMR, TP53 Mutated Advanced or Recurrent Endometrial Cancer

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

TrialFetch AI summary: Eligible patients are adults with advanced (stage III–IVA measurable, IVB ± measurable) or recurrent endometrial carcinoma that is mismatch repair–proficient and TP53-aberrant (p53 IHC aberrant or TP53-mutated), ECOG 0–2, with no prior PD-(L)1/CTLA-4 or anti-VEGF therapy and no prior chemo for endometrial cancer except adjuvant completed ≥12 months prior. Patients are randomized to first-line carboplatin/paclitaxel plus pembrolizumab (anti–PD-1) vs carboplatin/paclitaxel plus bevacizumab (anti–VEGF-A) vs carboplatin/paclitaxel plus pembrolizumab plus bevacizumab, followed by maintenance with the assigned biologic(s).

ClinicalTrials.gov ID: NCT07198074

A Phase I Clinical Trial of Carfilzomib in Combination With Sotorasib in Patients With KRASG12C Mutated Advanced Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: This trial evaluates the combination of carfilzomib, a proteasome inhibitor, and sotorasib, a KRAS G12C inhibitor, in adults with advanced or metastatic KRAS G12C-mutated non-small cell lung cancer who have progressed after previous KRAS inhibitor treatments.

ClinicalTrials.gov ID: NCT06249282

Phase I Study of Gilteritinib for ALK Positive Non-Small Cell Lung Cancer

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: The trial involves previously treated adult patients with stage IV ALK positive non-small cell lung cancer, evaluating the safety and optimal dosing of gilteritinib, an investigational drug that targets the FLT3 receptor tyrosine kinase. Patients must have progressed on first and second-generation ALK TKIs and may have had chemotherapy or other antineoplastic treatments.

ClinicalTrials.gov ID: NCT06225427

A Phase II Trial of Hepatic Ablation of Metastases to Modulate and Enhance Immunotherapy Response (HAMMER) in NSCLC

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial targets adults with stage IV NSCLC involving liver metastases, excluding those with EGFR or BRAF mutations and prior liver radiation, to evaluate the impact of adding liver stereotactic ablative radiotherapy (L-SABR) to a standard regimen of anti-PD-(L)1 based immunotherapy and optional platinum-based chemotherapy.

ClinicalTrials.gov ID: NCT05657873

An Open Label Phase II Study for the Treatment of Liver Metastatic Colorectal Cancer and Non-Small Cell Lung Cancer With a Combination of TATE (Trans-Arterial Tirapazamine Embolization) and Pembrolizumab

Moderate burden on patient

The trial has a moderate burden on patients. An example would be a trial testing an IV drug, with scans every 8 weeks which would be more frequent than standard of care.

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

TrialFetch AI summary: This trial evaluates the combination of Trans-Arterial Tirapazamine Embolization (TATE) and Pembrolizumab in patients with metastatic colorectal cancer (mCRC) and non-small cell lung cancer (NSCLC) who have liver metastases and have progressed after prior therapies. TATE delivers the hypoxia-activated prodrug Tirapazamine to liver tumors, while Pembrolizumab, an immune checkpoint inhibitor, blocks the PD-1 pathway to enhance anti-tumor immunity.

ClinicalTrials.gov ID: NCT04701476